such as jerking or twitching (chorea) difficulty with coordination trouble learning new information difficulty making decisions Juvenile and late onset forms of Huntington’s disease are also ...

The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.

Huntington’s disease is an inherited neurological disorder causing movement, cognitive, and behavioral issues. Effective management includes medical treatments, therapies, nutritional support, and ...

SOM3355 (bevantolol hydrochloride) hit its objectives in a phase 2 trial in patients with Huntington's disease, improving the involuntary, jerky movements known as chorea that are a key symptom of ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...

Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and ...

SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief ...

Multiple system atrophy (MSA) is not exactly a household word – a situation that Alterity Therapeutics is seeking to change.

In 2023, the company received FDA approval for valbenazine as a treatment for chorea associated with Huntington's disease. Valbenazine is in Phase 3 clinical studies as an adjunctive treatment ...